• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of gutGutCurrent TOCInstructions to authors
Gut. Oct 2000; 47(4): 527–532.
PMCID: PMC1728068

COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin

Abstract

BACKGROUND—Acute and chronic use of non-steroidal anti-inflammatory drugs can increase intestinal permeability. Rofecoxib, which selectively inhibits cyclooxygenase 2 (COX-2), is a novel anti-inflammatory drug with the potential to produce minimal gastrointestinal toxic effects while retaining clinical efficacy.
AIMS—To assess the potential for rofecoxib to affect the intestine adversely, in comparison with placebo and indomethacin.
SUBJECTS—Thirty nine healthy subjects (aged 24-30 years).
METHOD—We performed a four period crossover trial to assess intestinal permeability before and after seven days of treatment. Permeability was measured by the urinary ratio of chromium-51 labelled ethylene diamine tetraacetate (51CrEDTA)/L-rhamnose (five hour collection).
RESULTS—Indomethacin 50 mg three times daily produced greater increases in intestinal permeability compared with placebo or rofecoxib (25 or 50 mg) (p[less-than-or-eq, slant]0.001); rofecoxib was not significantly different from placebo. Mean day 7 to baseline ratios (95% confidence intervals) for 51CrEDTA/L-rhamnose were 0.97 (0.82, 1.16), 0.80 (0.68, 0.95), 0.98 (0.82, 1.17), and 1.53 (1.27, 1.85) for placebo, rofecoxib 25 mg, rofecoxib 50 mg, and indomethacin groups, respectively. Rofecoxib was generally well tolerated.
CONCLUSION—In this study, treatment for one week with indomethacin 50 mg three times daily significantly increased intestinal permeability compared with placebo, while treatment with rofecoxib 25 mg or 50 mg daily did not. The absence of a significant effect of rofecoxib on intestinal permeability at doses at least twice those recommended to treat osteoarthritis was consistent with other studies that have demonstrated little or no injury to the gastrointestinal mucosa associated with rofecoxib therapy.


Keywords: rofecoxib; COX-2 inhibitor; indomethacin; non-steroidal anti-inflammatory drugs; intestinal permeability; osteoarthritis

Full Text

The Full Text of this article is available as a PDF (150K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bjarnason I, Williams P, So A, Zanelli GD, Levi AJ, Gumpel JM, Peters TJ, Ansell B. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet. 1984 Nov 24;2(8413):1171–1174. [PubMed]
  • Segal AW, Isenberg DA, Hajirousou V, Tolfree S, Clark J, Snaith ML. Preliminary evidence for gut involvement in the pathogenesis of rheumatoid arthritis? Br J Rheumatol. 1986 May;25(2):162–166. [PubMed]
  • Bjarnason I, Zanelli G, Smith T, Prouse P, Williams P, Smethurst P, Delacey G, Gumpel MJ, Levi AJ. Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology. 1987 Sep;93(3):480–489. [PubMed]
  • Bjarnason I, Zanelli G, Prouse P, Smethurst P, Smith T, Levi S, Gumpel MJ, Levi AJ. Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet. 1987 Sep 26;2(8561):711–714. [PubMed]
  • Bjarnason I, Price AB, Zanelli G, Smethurst P, Burke M, Gumpel JM, Levi AJ. Clinicopathological features of nonsteroidal antiinflammatory drug-induced small intestinal strictures. Gastroenterology. 1988 Apr;94(4):1070–1074. [PubMed]
  • Bjarnason I, Zanelli G, Smith T, Smethurst P, Price AB, Gumpel MJ, Levi AJ. The pathogenesis and consequence of non steroidal anti-inflammatory drug induced small intestinal inflammation in man. Scand J Rheumatol Suppl. 1987;64:55–62. [PubMed]
  • Bjarnason I, Fehilly B, Smethurst P, Menzies IS, Levi AJ. Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man. Gut. 1991 Mar;32(3):275–277. [PMC free article] [PubMed]
  • Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology. 1993 Jun;104(6):1832–1847. [PubMed]
  • Somasundaram S, Hayllar H, Rafi S, Wrigglesworth JM, Macpherson AJ, Bjarnason I. The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol. 1995 Apr;30(4):289–299. [PubMed]
  • Mahmud T, Rafi SS, Scott DL, Wrigglesworth JM, Bjarnason I. Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Arthritis Rheum. 1996 Dec;39(12):1998–2003. [PubMed]
  • Bjarnason I, Smethurst P, Fenn CG, Lee CE, Menzies IS, Levi AJ. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci. 1989 Mar;34(3):407–411. [PubMed]
  • Bjarnason I, Williams P, Smethurst P, Peters TJ, Levi AJ. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut. 1986 Nov;27(11):1292–1297. [PMC free article] [PubMed]
  • Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993 Mar 25;268(9):6610–6614. [PubMed]
  • Fosslien E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci. 1998 Mar-Apr;28(2):67–81. [PubMed]
  • Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11693–11697. [PMC free article] [PubMed]
  • Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7563–7568. [PMC free article] [PubMed]
  • Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, et al. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther. 1999 Aug;290(2):551–560. [PubMed]
  • Ehrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, Porras A, Wittreich J, Seibold JR, De Schepper P, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther. 1999 Mar;65(3):336–347. [PubMed]
  • Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology. 1995 May;108(5):1566–1581. [PubMed]
  • Bjarnason I, Maxton D, Reynolds AP, Catt S, Peters TJ, Menzies IS. Comparison of four markers of intestinal permeability in control subjects and patients with coeliac disease. Scand J Gastroenterol. 1994 Jul;29(7):630–639. [PubMed]
  • Kendall MJ, Nutter S, Hawkins CF. Xylose test: effect of aspirin and indomethacin. Br Med J. 1971 Mar 6;1(5748):533–536. [PMC free article] [PubMed]
  • Dyer NH, Kendall MJ, Hawkins CF. Malabsorption in rheumatoid disease. Ann Rheum Dis. 1971 Nov;30(6):626–630. [PMC free article] [PubMed]
  • Menzies IS, Mount JN, Wheeler MJ. Quantitative estimation of clinically important monosaccharides in plasma by rapid thin layer chromatography. Ann Clin Biochem. 1978 Mar;15(2):65–76. [PubMed]
  • Lanza FL, Rack MF, Simon TJ, Quan H, Bolognese JA, Hoover ME, Wilson FR, Harper SE. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther. 1999 Jun;13(6):761–767. [PubMed]
  • Sigthorsson G, Tibble J, Hayllar J, Menzies I, Macpherson A, Moots R, Scott D, Gumpel MJ, Bjarnason I. Intestinal permeability and inflammation in patients on NSAIDs. Gut. 1998 Oct;43(4):506–511. [PMC free article] [PubMed]
  • Bjarnason I, Smethurst P, Clark P, Menzies I, Levi J, Peters T. Effect of prostaglandin on indomethacin-induced increased intestinal permeability in man. Scand J Gastroenterol Suppl. 1989;164:97–103. [PubMed]
  • Bjarnason I, Zanelli G, Smith T, Prouse P, Williams P, Smethurst P, Delacey G, Gumpel MJ, Levi AJ. Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology. 1987 Sep;93(3):480–489. [PubMed]

Figures and Tables

Figure 1
Five hour geometric mean urinary excretion ratios for 51CrEDTA/L-rhamnose at baseline and on day 7 for subjects who received placebo, rofecoxib 25 mg, rofecoxib 50 mg, and indomethacin 150 mg (per protocol analysis). Indomethacin ...
Figure 2
Day 7 to baseline geometric mean ratios (with 95% confidence intervals) for five hour urinary excretion of 51CrEDTA/L-rhamnose in subjects who received placebo, rofecoxib 25 mg, rofecoxib 50 mg, and indomethacin 150 mg ...

Articles from Gut are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...